You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 8,475,790

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,475,790

Title:	Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
Abstract:	Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
Inventor(s):	Jure-Kunkel; Maria (Plainsboro, NJ)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	13/122,630
Patent Claims:	1. A method for diminishing the incidence or severity of immunotherapy-dependent colitis associated with anti-CTLA4 therapy comprising administering to a mammal in need thereof a combination comprising the sequential administration of a therapeutically effective amount of an agonistic CD137 antibody, followed by the administration of a therapeutically effective amount of an antagonistic CTLA-4 antibody, wherein the incidence or severity of immunotherapy-dependent colitis associated with anti-CTLA4 therapy is diminished. 2. The method according to claim 1 comprising an interstitial period in between said administrations. 3. The method according to claim 2 wherein said interstitial period is one day. 4. The method according to claim 2 wherein said interstitial period is between 18 to 24 hours. 5. The method according to claim 2 wherein said interstitial period is between 12 to 18 hours. 6. The method according to claim 2 wherein said interstitial period is less than 12 hours. 7. The method according to claim 1 wherein the antagonistic CTLA-4 antibody is ipilimumab. 8. The method according to claim 1 wherein the antagonistic CTLA-4 antibody is tremelimumab.

Details for Patent 8,475,790

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011	⤷ Try a Trial	2028-10-06
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.